A Phase II/III Study of Cyclotron-produced Tc-99m Pertechnetate (C-PERT) Efficacy and Safety in Patients With Conformed and Suspected Thyroid Cancer or Head and Neck Cancer
Doctors at the Cross Cancer Institute have developed a new method of producing 99mTc
Pertechnetate in a cyclotron unit. A study done at the Cross Cancer Institute in 2011 with
ten patients using this imaging agent showed that it was safe and produced images with the
same pattern as generator produced Pertechnetate. This study is now being done in larger
numbers of patients to again show that the imaging pattern of both agents is the same, and
to again demonstrate its safety.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society